Literature DB >> 35070408

LncRNA-CASC7 inhibits the proliferation and migration of colon cancer by negatively regulating the PI3K/Akt signaling pathway.

Bo Hao1, Hexin Wen1, Yingying Sun2, Zhenghong Le1, Zongbing Zhang1, Mulin Liu1, Ting Hu3.   

Abstract

BACKGROUND: This study aims to investigate the effect of LncRNA-CASC7 (cancer susceptibility candidate 7) on the proliferation and migration of colon cancer cells and its possible mechanism.
METHODS: In this study, quantitative real-time polymerase chain reaction (qRT-PCR) was employed for the detection of lncRNA-CASC7 expression in 54 colon cancer tissues and 5 colon cancer cell lines. This study aimed to evaluate the significant correlation between the lncRNA-CASC7 expression, the clinical features, and the survival rate of patients. LncRNA-CASC7 was overexpressed by lipofectin transfection. Cell proliferation was detected by the methyl thiazolyl tetrazolium (MTT) assay. Transwell assay was conducted to examine cell migration and invasion. The target gene was verified by dual fluorescein. The expression of proliferation and invasion-related proteins was detected via western blotting (WB).
RESULTS: The LncRNA-CASC7 expression in colon cancer was considerably decreased than in nearby healthy tissues (P<0.01). Its expression level was linked to survival rate, lymph node metastasis, and tumor node metastasis (TNM) stage. Similarly, the expression of lncRNA-CASC7 was decreased in 5 colon cancer cell lines. The proliferative, invasive, and migratory potential of cells was considerably decreased by lncRNA-CASC7 overexpression. Overexpression of lncRNA-CASC7 significantly inhibited the expression of proteins Ki-67 and PNCA (associated with proliferation) and proteins N-cadherin, E-cadherin, and vimentin (linked with metastasis). Further studies showed that overexpression of LncRNA-CASC7 could significantly inhibit the PI3K/Akt signaling pathway in colon cancer cells.
CONCLUSIONS: The PI3K/Akt signaling cascade is negatively regulated by LncRNA-CASC7, which serves as a tumor suppressor gene by attenuating colon cancer cell proliferation, invasion, and migration, thus affecting the tumor progression and prognosis of colon cancer patients. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  LncRNA-CASC7; colon cancer; migration; proliferation

Year:  2021        PMID: 35070408      PMCID: PMC8748023          DOI: 10.21037/jgo-21-643

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  25 in total

Review 1.  LncRNA: a link between RNA and cancer.

Authors:  Guodong Yang; Xiaozhao Lu; Lijun Yuan
Journal:  Biochim Biophys Acta       Date:  2014-08-23

Review 2.  Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives.

Authors:  Antara Banerjee; Surajit Pathak; Vimala Devi Subramanium; Dharanivasan G; Ramachandran Murugesan; Rama S Verma
Journal:  Drug Discov Today       Date:  2017-05-22       Impact factor: 7.851

3.  Analysis of lncRNA-Associated ceRNA Network Reveals Potential lncRNA Biomarkers in Human Colon Adenocarcinoma.

Authors:  Zhiyuan Zhang; Wenwei Qian; Sen Wang; Dongjian Ji; Qingyuan Wang; Jie Li; Wen Peng; Jiou Gu; Tao Hu; Bing Ji; Yue Zhang; Shijia Wang; Yueming Sun
Journal:  Cell Physiol Biochem       Date:  2018-09-19

4.  Hydrogen sulfide upregulated lncRNA CasC7 to reduce neuronal cell apoptosis in spinal cord ischemia-reperfusion injury rat.

Authors:  Yang Liu; Lei Pan; Ao Jiang; Min Yin
Journal:  Biomed Pharmacother       Date:  2018-01-06       Impact factor: 6.529

5.  LncRNA-CASC7 enhances corticosteroid sensitivity via inhibiting the PI3K/AKT signaling pathway by targeting miR-21 in severe asthma.

Authors:  Jian-Hua Liu; Chen Li; Chang-Hong Zhang; Zhi-Hua Zhang
Journal:  Pulmonology       Date:  2019-08-11

6.  LncRNA LINC00628 overexpression inhibits the growth and invasion through regulating PI3K/Akt signaling pathway in osteosarcoma.

Authors:  R He; J-X Wu; Y Zhang; H Che; L Yang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-09       Impact factor: 3.507

7.  An Integrated miRNA-lncRNA Signature Predicts the Survival of Stage II Colon Cancer.

Authors:  Xiao-Jie Wang; Bing Zeng; Shuangming Lin; Min Chen; Pan Chi
Journal:  Ann Clin Lab Sci       Date:  2019-11       Impact factor: 1.256

8.  NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

Authors:  Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Lynette Cederquist; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Ignacio Garrido-Laguna; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Eric D Miller; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Evan Wuthrick; Kristina M Gregory; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

9.  LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway.

Authors:  Yanxia Huang; Jing Zhang; Lidan Hou; Ge Wang; Hui Liu; Rui Zhang; Xiaoyu Chen; Jinshui Zhu
Journal:  J Exp Clin Cancer Res       Date:  2017-12-28

10.  Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides.

Authors:  Kim A Lennox; Mark A Behlke
Journal:  Nucleic Acids Res       Date:  2015-11-17       Impact factor: 16.971

View more
  1 in total

1.  Expression of Long Nonencoding Ribonucleic Acid SNHG20 in Colon Cancer Tissue in Its Influences on Chemotherapeutic Sensitivity of Colon Cancer Cells.

Authors:  Wenbin Cao; Bo Zhang; Yang Liu
Journal:  Biomed Res Int       Date:  2022-07-23       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.